Staurosporine, Protein kinase inhibitor
Be the first to review this product! Submit a review
|
(34 Publications)
- Competitive inhibition at the ATP binding site
- Chemical Structure
Lab
Chemical Structure - Staurosporine, Protein kinase inhibitor (AB120056)
2D chemical structure image of ab120056, Staurosporine, Protein kinase inhibitor
- FuncS
Unknown
Functional Studies - Staurosporine, Protein kinase inhibitor (AB120056)
Example of IC50 determination. HeLa cells were treated with a dose titration of Staurosporine for 4 hours in complete media. Cells were cultured and treated in a 96-well cell culture microtiter plate. Lysates were prepared by direct in-well lysis without media removal : 2X Cell Extraction Buffer PTR was added to an equal volume of media and then resulting lysate was used directly in the Cleaved PARP SimpleStepTM ELISA assay. Raw values for triplicate measurements are plotted. The calculated IC50 is 0.77 μM.
- FuncS
Unknown
Functional Studies - Staurosporine, Protein kinase inhibitor (AB120056)
Example of HeLa staurosporine (ab120056) treated cell lysate titration. Background-subtracted data values (mean +/- SD) are graphed.
- FuncS
Unknown
Functional Studies - Staurosporine, Protein kinase inhibitor (AB120056)
HeLa and Jurkat cells were treated with 1 µM Staurosporine (STS) (ab120056) for 4 hours in complete cell culture media to induce apoptosis and cleaved PARP protein. Untreated and STS treated HeLa and Jurkat lysates were prepared in 1X Cell Extraction Buffer PTR and tested the Cleaved PARP SimpleStepTM ELISA. Raw OD 450 nm values are shown for 500 µg/mL lysate loads.
- FuncS
Unknown
Functional Studies - Staurosporine, Protein kinase inhibitor (AB120056)
Demonstration of Cleaved PARP capture antibody specificity by western blot assay. 20 μg of HeLa extracts that were untreated or treated for 4 hours with 1 μM Staurosporine were analyzed by western blot. The GAPDH blot is included to show the relative loads of each lysate. In the HeLa cell line, Staurosporine treatment is required to detect cleaved PARP protein, as observed in the SimpleStep ELISA.
- FuncS
Unknown
Functional Studies - Staurosporine, Protein kinase inhibitor (AB120056)
Lane 1 : HeLa, vehicle (DMSO) treated for 4 hours Lane 2 : HeLa 1 μM staurpsorine (ab120056), 4 hours Load 20 μg/lane 5% milk/PBST for block and antibody diluent Primary antibodies (2 hours, room temp) All lanes : ab136812 250X Primary Antibodies Cocktail, 1/250 dilution Secondary antibodies (1 hour, room temp) All lanes : ab136812 100X HRP-Conjugated Secondary Antibodies Cocktail, 1/100 dilution
Product details
Properties and storage information
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Pathways
Several PKC isoforms engage critical cell signaling pathways such as the MAPK/ERK pathway and the PI3K/AKT pathway. In these pathways PKCs modulate various downstream effectors coordinating signals that influence gene expression and cell survival. PKC delta has significant associations with the MAPK cascade while PKC theta interacts closely with PI3K. These interactions are necessary for linking external signals to intracellular responses thereby acting as converging points for signaling pathways impacting multiple cellular functions.
Biological function summary
PKC isoforms regulate cellular functions like proliferation differentiation and apoptosis. These proteins are part of larger signaling complexes participating in dynamic equilibrium states that determine cellular fate. For example PKC epsilon often interacts within complexes modulating oncogenic pathways while PKC beta 2 plays roles in immune response modulation. The distinct expression patterns and interactions of these isoforms enable them to assume specific biological roles in different tissues.
Publications (34)
Recent publications for all applications. Explore the full list and refine your search
Journal of translational medicine 22:868 PubMed39334383
2024
Applications
Unspecified application
Species
Unspecified reactive species
The EMBO journal 43:5237-5259 PubMed39271794
2024
Applications
Unspecified application
Species
Unspecified reactive species
Neurobiology of stress 28:100593 PubMed38075025
2023
Applications
Unspecified application
Species
Unspecified reactive species
iScience 26:108080 PubMed37860693
2023
Applications
Unspecified application
Species
Unspecified reactive species
iScience 26:107323 PubMed37529105
2023
Applications
Unspecified application
Species
Unspecified reactive species
Brain : a journal of neurology 146:4378-4394 PubMed37070763
2023
Applications
Unspecified application
Species
Unspecified reactive species
Rheumatology (Oxford, England) 62:3197-3204 PubMed36708011
2023
Applications
Unspecified application
Species
Unspecified reactive species
Cancers 13: PubMed34572749
2021
Applications
Unspecified application
Species
Unspecified reactive species
PLoS pathogens 17:e1009458 PubMed34383863
2021
Applications
Unspecified application
Species
Unspecified reactive species
Nature 596:262-267 PubMed34349263
2021
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com